Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies including Multiple Myeloma: Study NPI-0052-102 Final Results.

CONCLUSIONS: Marizomib does not exhibit the severe peripheral neuropathy or hematological toxicity observed with other proteasome inhibitors. Marizomib was generally well tolerated with low-dose dexamethasone, demonstrated activity in heavily pretreated RRMM patients, and warrants further evaluation.
PMID: 27117181 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 25, 2016 Category: Cancer & Oncology Authors: Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, Cannell PK, Reich SD, Trikha M, Spencer A Tags: Clin Cancer Res Source Type: research